๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Small Cell Lung Cancer Metastatic or Locally Advanced

A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site๐Ÿ“ Hangzhou Betta Pharmaceuticals Co., Ltd. ยท Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8โ€ฆ A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Boston Taiho Oncology, Inc. ยท Tests: TAS6417, CYP Cocktail, Transporter Cocktail A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites๐Ÿ“ Hefei๐Ÿ“ Harbin๐Ÿ“ Wuhan Abbisko Therapeutics Co, Ltd ยท Tests: ABSK043 in combination with Firmonertinib A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites๐Ÿ“ Bakersfield๐Ÿ“ Beverly Hills๐Ÿ“ Stamford Merck Sharp & Dohme LLC ยท Tests: Calderasib, Placebo, Pembrolizumab ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site๐Ÿ“ Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. ยท Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site๐Ÿ“ Nanchang Second Affiliated Hospital of Nanchang University ยท Tests: Vebreltinib, Furmonertinib 80mg A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site๐Ÿ“ Taipei AP Biosciences Inc. ยท Tests: AP203, AP203 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) NCT07149649Phase 2, Phase 311 sites๐Ÿ“ Aarau๐Ÿ“ Aarau๐Ÿ“ Baden Swiss Cancer Institute ยท Tests: Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose, Isotonic saline solution 0.9% Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT05168566Phase 231 sites๐Ÿ“ Glendale๐Ÿ“ Washington D.C.๐Ÿ“ Athens Teligene US ยท Tests: Sutetinib Maleate Capsule Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Disitamab Vedotin + tislelizumab + bevacizumab Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C NCT05631249Phase 25 sites๐Ÿ“ Lyon๐Ÿ“ Marseille๐Ÿ“ Paris Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Sotorasib 120Mg Tab Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site๐Ÿ“ Guangzhou Avistone Biotechnology Co., Ltd. ยท Tests: PLB1004 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure NCT06300177Phase 386 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ยท Tests: D-1553 Tablet, Docetaxel injection A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites๐Ÿ“ Springdale๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality NCT06496490Phase 225 sites๐Ÿ“ Fuzhou๐Ÿ“ Foshan๐Ÿ“ Guangzhou Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharโ€ฆ ยท Tests: TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure๏ผšPhase I/II NCT06195189Phase 1, Phase 21 site๐Ÿ“ Chengdu Sichuan University ยท Tests: Sunvozertinib, Chemotherapy A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites๐Ÿ“ Birmingham๐Ÿ“ Los Angeles๐Ÿ“ Miami Astellas Pharma Global Development, Inc. ยท Tests: ASP546C A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816Phase 21 site๐Ÿ“ Wuhan Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, Pembrolizumab Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) NCT06809764n/a36 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Daiichi Sankyo ยท Tests: No drug Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) NCT05559645NA1 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: DZD9008, DZD9008 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738Phase 3328 sites๐Ÿ“ Tucson๐Ÿ“ Springdale๐Ÿ“ Anaheim AstraZeneca ยท Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites๐Ÿ“ Santa Monica๐Ÿ“ New Have๐Ÿ“ Camperdown Kivu Bioscience Inc. ยท Tests: KIVU-107 Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy NCT04691817Phase 1, Phase 21 site๐Ÿ“ Philadelphia Abramson Cancer Center at Penn Medicine ยท Tests: Atezolizumab, Tocilizumab A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M09D1 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer NCT07416994Phase 32 sites๐Ÿ“ Shanghai๐Ÿ“ Hangzhou MediLink Therapeutics (Suzhou) Co., Ltd. ยท Tests: YL202, Docetaxel ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI NCT06388031Phase 21 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Immune checkpoint inhibitor A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300Phase 21 site๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy